Capricor Therapeutics (NASDAQ:CAPR) is a clinical-stage biotechnology company headquartered in Los Angeles, California, specializing in the development of innovative cell and exosome-based therapies. Since its founding in 2008, Capricor has focused on leveraging its proprietary platforms to address serious, unmet medical needs in cardiovascular and neuromuscular diseases. The company’s research and development efforts center on advancing novel biologics that harness the regenerative and immunomodulatory potential of human cells and extracellular vesicles.
The company’s lead product candidate, CAP-1002, comprises allogeneic cardiosphere-derived cells (CDCs) designed to repair and regenerate damaged heart tissue. CAP-1002 has been evaluated in clinical trials for indications including Duchenne muscular dystrophy-associated cardiomyopathy and acute COVID-19-related respiratory distress. These studies have demonstrated favorable safety profiles and signs of functional improvement, positioning CAP-1002 as a potential therapeutic option in conditions where conventional treatments are limited.
Building on its cell therapy expertise, Capricor is expanding into the rapidly evolving field of extracellular vesicles with its exosome platform. The company’s investigational exosome product candidate, CAP-2003, is engineered to deliver microRNA payloads that modulate key pathways in heart disease and immune response. This approach seeks to capitalize on exosomes’ natural ability to circulate systemically, offering targeted delivery with minimized risk of rejection or off-target effects.
Under the leadership of President and Chief Executive Officer Linda Marbán, Ph.D., Capricor has formed strategic collaborations with academic institutions, government agencies, and industry partners to advance its pipeline. The company’s multidisciplinary team of scientists and clinicians is dedicated to translating cutting-edge discoveries into scalable therapies. With a commitment to rigorous clinical development and manufacturing excellence, Capricor continues to pursue breakthroughs that may transform the standard of care for patients with debilitating cardiovascular and muscular disorders.
